GeneNews Limited
TSX : GEN

GeneNews Limited

May 05, 2010 11:48 ET

GeneNews to Feature ColonSentry™ at the 8th Annual Primary Care Today Conference

TORONTO, ONTARIO--(Marketwire - May 5, 2010) - GeneNews Limited (TSX:GEN), an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management, today announced that it will be exhibiting at the Primary Care Today educational conference and medical exposition being held at the International Center, May 6-8, 2010 in Toronto. GeneNews' exhibit, at booth No. 1108, will feature the Company's lead product, ColonSentry™, the world's first blood-based test to determine a person's current risk for colorectal cancer.

"Primary Care Today is produced in partnership with Canada's largest medical school, the University of Toronto's Department of Family & Community Medicine, and is expected to attract more than 2,000 family physicians, general practitioners and healthcare professionals," said Gailina J. Liew, President and Chief Operating Officer of GeneNews. "We believe that increasing doctor awareness and acceptance of ColonSentry™ through our participation in events like this will go a long way towards achieving our goal of expanded adoption and use of the test in Canada."

About GeneNews

GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has been granted two U.S. patents for its core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews launched its first commercial product, ColonSentry™, a blood-based test to assess an individual's risk for colorectal cancer, in Canada in 2008. The Company expects ColonSentry™ to be introduced to the New York and New Jersey markets, through GeneNews' exclusive partnership for these U.S. states with Enzo Clinical Labs (NYSE:ENZ), in the second half of 2010. For more information on GeneNews and ColonSentry™, visit http://www.genenews.com and http://www.colonsentry.com.

Forward-Looking Statements

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

Contact Information